About
Technology
Issues
FAQ
Links
Official Page
Sequential use of new agents (NAs) after docetaxel (DOC) first line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A pooled-analysis of the published studies.
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.